# Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Canonical URL: https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-completes-patient-enrollment-ahead-of-schedule-in-phase-2-phalcon-eoe-201-study-of-voqueznar-vonoprazan-in-eosinophilic-esophagitis-eoe
Ticker: PHAT
Company: Phathom Pharmaceuticals
Source: Phathom Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.phathompharma.com
## Summary

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc.

## Article Body
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc.
## Recent Company News
- 2026-06-25 13:46 EST — [Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-completes-patient-enrollment-ahead-of-schedule-in-phase-2-phalcon-eoe-201-study-of-voqueznar-vonoprazan-in-eosinophilic-esophagitis-eoe) — Source: Phathom Pharmaceuticals
- 2026-06-25 13:46 EST — [Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-highlights-breadth-of-independent-vonoprazan-research-at-digestive-disease-week-2026-annual-meeting) — Source: Phathom Pharmaceuticals
- 2026-06-25 13:46 EST — [Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Phathom Pharmaceuticals
- 2026-06-25 13:46 EST — [Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-announces-pricing-of-130-million-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Phathom Pharmaceuticals
- 2026-06-25 13:46 EST — [Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026) — Source: Phathom Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)